GlassScriptPhysician profile
Denisa Riera
NPI 1356731244
$9,430.43
in general payments reported to CMS, 2019-2025
43 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $450 · 2021: $925 · 2022: $1,429 · 2023: $1,172 · 2024: $2,715 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170 · Travel and Lodging: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,170.05 |
| Travel and Lodging | $742.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,599.54 | 2019-2025 | Collagenase Santyl, Pico, Renasys Touch |
| Mimedx Group, INC. | $1,352.71 | 2024-2025 | |
| Organogenesis INC. | $840.79 | 2019-2025 | Puraply Franchise, Affinity, Apligraf |
| Paratek Pharmaceuticals, INC. | $538.86 | 2021-2025 | Nuzyra |
| Stryker Corporation | $451.58 | 2019-2025 | Dart-Fire, Augment Injectable, Variax |
| Horizon Therapeutics Plc | $365.46 | 2019-2023 | Krystexxa |
| Kerecis Limited | $328.38 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Convatec INC. | $312.98 | 2019-2025 | |
| Triad Life Sciences INC. | $310.61 | 2022 | |
| Kci USA, INC. | $208.32 | 2019-2023 | Tegaderm, Promogran Prisma, 3m Coban |
| Melinta Therapeutics, LLC | $159.51 | 2021-2022 | |
| Solventum Corporation | $154.25 | 2024-2025 | Promogran Prisma, V.A.C.Ulta, V.A.C. Veraflo |
| Ibsa Pharma INC. | $135.22 | 2021-2023 | Tirosint, Licart |
| Amgen INC. | $129.47 | 2024-2025 | Krystexxa |
| Bioventus LLC | $124.34 | 2019-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osiris Therapeutics INC. | $123.16 | 2019 | |
| Next Science LLC | $113.54 | 2021-2023 | Xperience, Surgx, Blastx |
| Baudax Bio INC. | $112.16 | 2020-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Treace Medical Concepts, INC. | $96.31 | 2024-2025 | |
| Acera Surgical, INC. | $91.50 | 2019-2024 | Restrata Wound Matrix |
| Grt US Holding, INC. | $83.78 | 2021-2022 | |
| Orthofix Medical, INC. | $83.10 | 2019-2024 | Accelstim, Physio-Stim |
| Merck Sharp & Dohme LLC | $73.95 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.19 | 2021-2025 | Jublia |
| Averitas Pharma INC. | $47.30 | 2024 | Qutenza |
| Nabriva Therapeutics, Plc | $41.79 | 2020-2022 | |
| Sebela Pharmaceuticals INC. | $36.29 | 2021-2022 | |
| Bone Support INC. | $35.90 | 2024 | Ceramentbone Void Filler, Cerament G |
| Kowa Pharmaceuticals America, INC. | $35.63 | 2022 | |
| Medtronic, INC. | $30.67 | 2023 | Venaseal |
| Misonix INC | $28.44 | 2021 | |
| Reprise Biomedical, INC. | $28.18 | 2025 | Miro3d |
| Takeda Pharmaceuticals U.S.A., INC. | $25.61 | 2024 | Entyvio |
| Axogen | $23.13 | 2022 | |
| Hydrofera LLC | $22.83 | 2025 | Hydrofera Blue Ready - Border |
| Abbvie INC. | $22.30 | 2024 | |
| Lifenet Health | $21.25 | 2024 | Theragenesis Wound Matrix |
| Chiesi USA, INC. | $20.98 | 2025 | Filsuvez |
| Sanara Medtech INC. | $19.80 | 2025 | Celleraterx |
| Acell, INC. | $19.06 | 2020 | |
| Integra Lifesciences Corporation | $17.01 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Zimmer Biomet Holdings, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denisa Riera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.